# A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

> **NCT02890069** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 298 (actual)

## Conditions studied

- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** PDR001
- **DRUG:** LCL161
- **DRUG:** Everolimus
- **DRUG:** Panobinostat
- **DRUG:** QBM076
- **DRUG:** HDM201

## Key facts

- **NCT ID:** NCT02890069
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-14
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890069, "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02890069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*